Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, offers his expert perspective on single-arm drug approvals for targeted agents between 2016 and 2020, the need for biomarker testing, and the societal costs of drug development (Abstract PL04.03).
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated n...
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given ...
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...
Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated exten...
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success fo...